Search

William J Querbes

age ~72

from Clifton Park, NY

Also known as:
  • William T Querbes
  • William M Querbes
  • Bill Querbes
Phone and address:
12 Nicole Ct, Clifton Park Center, NY 12065
845 399-5233

William Querbes Phones & Addresses

  • 12 Nicole Ct, Clifton Park, NY 12065 • 845 399-5233
  • 2413 Parkville Pl, Niskayuna, NY 12309 • 518 346-4654
  • 2317 Niskayuna St, Schenectady, NY 12309 • 518 370-1642
  • Somerville, MA
  • Troy, NY

Us Patents

  • Lipid Formulation

    view source
  • US Patent:
    20120101148, Apr 26, 2012
  • Filed:
    Jan 29, 2010
  • Appl. No.:
    13/147189
  • Inventors:
    Akin Aking - Cambridge MA, US
    William Querbes - Cambridge MA, US
    Frances M.P. Wong - South Easton MA, US
    Joseph R. Dorkin - Cambridge MA, US
    Xiaojun Qin - Cambridge MA, US
    William Cantley - Cambridge MA, US
    Anna Borodovsky - Cambridge MA, US
    Soma De - Cambridge MA, US
    Muthiah Manoharan - Cambridge MA, US
    Muthusamy Jayaraman - Cambridge MA, US
  • Assignee:
    ALNYLAM PHARMACEUTICALS, INC. - Cambridge MA
  • International Classification:
    A61K 31/713
    A61P 43/00
    A61K 31/7088
    A61K 47/42
    A61K 47/28
    A61K 31/7105
  • US Classification:
    514 44 A, 514788, 514 44 R, 514777, 514773
  • Abstract:
    The invention features an improved lipid formulation comprising a cationic lipid of formula (A), a neutral lipid, a sterol and a PEG or PEG-modified lipid, where Rand Rare independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and Rand Rare independently lower alkyl or Rand Rcan be taken together to form an optionally substituted heterocyclic ring. In one embodiment, Rand Rare independently selected from oleoyl, pamitoyl, steroyl, linoleyl and Rand Rare methyl. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
  • Compositions And Methods For Inhibiting Expression Of The Alas1 Gene

    view source
  • US Patent:
    20130281511, Oct 24, 2013
  • Filed:
    Mar 15, 2013
  • Appl. No.:
    13/835613
  • Inventors:
    Brian Bettencourt - Cambridge MA, US
    Kevin Fitzgerald - Brookline MA, US
    William Querbes - Cambridge MA, US
    Robert J. Desnick - New York NY, US
    Makiko Yasuda - New York NY, US
  • International Classification:
    C12N 15/113
  • US Classification:
    514 44 A, 536 245, 435325, 435375, 4353201
  • Abstract:
    The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
  • Compositions And Methods For Increasing Erythropoietin (Epo) Production

    view source
  • US Patent:
    20140024699, Jan 23, 2014
  • Filed:
    Dec 9, 2011
  • Appl. No.:
    13/992334
  • Inventors:
    Victor Kotelianski - Cambridge MA, US
    William Querbes - Cambridge MA, US
    Brian Bettencourt - Cambridge MA, US
  • Assignee:
    DANA-FARBER CANCER INSTITUTE - Boston MA
    ALNYLAM PHARMACEUTICALS, INC. - Cambridge MA
  • International Classification:
    C12N 15/113
  • US Classification:
    514 44 A, 536 245, 435325, 435375
  • Abstract:
    The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
  • Delivery Of Rnai Constructs To Oligodendrocytes

    view source
  • US Patent:
    20110118340, May 19, 2011
  • Filed:
    Feb 6, 2009
  • Appl. No.:
    12/866444
  • Inventors:
    Muthiah Manoharan - Cambridge MA, US
    Dinah Sah - Cambridge MA, US
    William Querbes - Cambridge MA, US
    Pamela Tan - Kulmbach, DE
    Qingmin Chen - Cambridge MA, US
  • International Classification:
    A61K 31/7088
    A61P 31/12
    A61P 25/00
    A61P 25/18
    A61P 25/16
    A61P 25/28
  • US Classification:
    514 44 R
  • Abstract:
    The invention provides methods for delivering a double-stranded nbonucleic acid (dsRNA) to the central nervous system of a subject, and particularly, to oligodendrocytes of a subject by localized delivery to the brain, e.g., to the corpus caïlosum. For example, the dsRNA molecules can include a first sequence that is selected from the Sroup consisting of the sense sequences of Tables 8, 10, 13-16, and a second sequence selected from the group consisting of the antisense sequences of Tables 8, 10, and 13-16. The dsRNA molecules can include naturally occurring nucleotides or can include at least one modified nucleotide, such as a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, or a terminal nucleotide linked to a conjugate group, such as to a cholesteryl derivative or a vitamin E group. Alternatively, the modified nucleotide may be chosen from the group consisting of a 2f-deoxy-2′-fliιioro modified nucleotide, a 2′-de-oxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural bas comprising nucleotide. Generally, such modified sequences will be based on a first sequence of a dsRNA selected from the group consisting of the sense sequences of Tables 8, 10, and 13-16, and a second sequence selected from the group consisting of the antisense sequences of Tables 8 10, and 13-16.
  • Compositions And Methods For Inhibiting Expression Of The Alas1 Gene

    view source
  • US Patent:
    20220403382, Dec 22, 2022
  • Filed:
    Feb 8, 2021
  • Appl. No.:
    17/170648
  • Inventors:
    - Cambridge MA, US
    - New York NY, US
    William Querbes - Cambridge MA, US
    Robert J. Desnick - New York NY, US
    Makiko Yasuda - New York NY, US
  • International Classification:
    C12N 15/113
    A61K 31/713
    A61K 47/60
    A61K 48/00
  • Abstract:
    The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
  • Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use Thereof

    view source
  • US Patent:
    20220235358, Jul 28, 2022
  • Filed:
    Apr 6, 2022
  • Appl. No.:
    17/714196
  • Inventors:
    - Cambridge MA, US
    William Querbes - Boston MA, US
    Kevin Fitzgerald - Brookline MA, US
    Stuart Milstein - Arlington MA, US
    Svetlana Shulga Morskaya - Sudbury MA, US
  • International Classification:
    C12N 15/113
    A61K 31/713
    A61K 31/7105
  • Abstract:
    The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
  • Apolipoprotein C3 (Apoc3) Irna Compositions And Methods Of Use Thereof

    view source
  • US Patent:
    20230068339, Mar 2, 2023
  • Filed:
    May 11, 2022
  • Appl. No.:
    17/741550
  • Inventors:
    - Cambridge MA, US
    William QUERBES - Boston MA, US
    James BUTLER - Lynnfield MA, US
    Stephanie WILLIAMS - Littleton MA, US
    Abigail LIEBOW - Somerville MA, US
    Gregory HINKLE - Plymouth MA, US
    Martin A. MAIER - Belmont MA, US
    Stuart MILSTEIN - Arlington MA, US
    Satyanarayana KUCHIMANCHI - Acton MA, US
    Muthiah MANOHARAN - Weston MA, US
  • International Classification:
    C12N 15/113
    A61P 3/04
    A61P 43/00
    A61P 13/12
    A61P 1/18
    A61P 3/10
    A61P 9/12
    A61P 15/08
    A61P 9/10
    A61P 1/16
    A61P 3/06
    A61K 31/713
  • Abstract:
    The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
  • Compositions And Methods For Inhibiting Expression Of The Alas1 Gene

    view source
  • US Patent:
    20230026968, Jan 26, 2023
  • Filed:
    May 4, 2021
  • Appl. No.:
    17/307846
  • Inventors:
    - Cambridge MA, US
    - New York NY, US
    William Querbes - Cambridge MA, US
    Robert J. Desnick - New York NY, US
    Makiko Yasuda - New York NY, US
  • International Classification:
    C12N 15/113
    A61K 9/00
    C12Q 1/6876
  • Abstract:
    The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

Get Report for William J Querbes from Clifton Park, NY, age ~72
Control profile